PAH News

April 4, 2019April 18, 2019

Systemic Hypertension a Predictor of PAH in Lupus Patients, Retrospective Study Finds

News, PAH News

Systemic hypertension is an independent predictor in rare cases of pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE), a retrospective large-cohort study in Taiwan shows. According to the ... Read more

April 3, 2019April 3, 2019

Researchers ID Genetic Factor That Predisposes Carriers of Specific Mutation to Familial PAH

News, PAH News

Variations in a gene called FIGN predispose to familial or heritable pulmonary arterial hypertension (FPAH) in carriers of the p.Arg491Gln mutation at the BMPR2 gene, according to a study looking at ... Read more

April 1, 2019April 1, 2019

Increased Production of Nestin Protein Involved in PAH Development, Study Suggests

News, PAH News

Increased production of a protein called Nestin by cells lining the blood vessels in the lungs may contribute to the development and progression of pulmonary arterial hypertension (PAH), a ... Read more

March 28, 2019April 18, 2019

Sandoz Launches Treprostinil Injection, First Remodulin Generic, in the US for PAH Treatment

News, PAH News

The pharmaceutical company Sandoz announced the commercialization of an injectable form of the vasodilating therapy treprostinil for treating exercise-related symptoms affecting individuals with pulmonary arterial hypertension (PAH). This treprostinil ... Read more

March 27, 2019April 4, 2019

Bcl-xL Is a Potential New Therapeutic Target for PAH, Researchers Say

News, PAH News

Mutations in the BMPR2 gene alter the ratio of pro- and anti-death signals in cells lining the blood vessels, promoting cells destined to die to escape, which in turn culminates ... Read more

March 21, 2019March 27, 2019

Resverlogix Obtains Funding for Phase 2 Trial Testing Apabetalone in PAH

News, PAH News

Resverlogix announced that it has received funding from the Canadian Institutes for Health Research for a Phase 2 clinical study investigating the safety and efficacy of its proprietary therapy apabetalone (RVX-208) ... Read more

March 20, 2019March 26, 2019

Opsumit Has Potential to Improve Right Ventricle Function in PAH Patients, Phase 4 Data Show

News, PAH News

Treatment with Opsumit (macitentan) can significantly improve the heart’s right ventricular function, reverse cardiac tissue remodeling, and reduce pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH), preliminary ... Read more

March 18, 2019March 26, 2019

Cell Therapies Show Potential as Treatment for PAH, Review Finds

News, PAH News

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such ... Read more

March 15, 2019March 22, 2019

Estrogen May Help Protect Against Heart Changes in PAH, Animal Study Suggests

News, PAH News

Estrogen, one of the major female sex hormones, has a protective effect in pulmonary arterial hypertension (PAH) by halting oxidative stress and collagen deposition, a rat study suggests. The ... Read more

March 14, 2019March 19, 2019

Liquidia’s LIQ861 Safe and Effective in PAH Patients, Phase 3 Trial Suggests

News, PAH News

A Phase 3 clinical trial testing LIQ861 met its primary objective, showing that the investigational inhaled dry powder treprostinil formulation is safe and effective for the treatment of pulmonary arterial hypertension (PAH), according ... Read more

Pin It on Pinterest